On February 3, 2021 Eli Lilly and Company (NYSE: LLY) reported that it will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021 (Press release, Eli Lilly, FEB 3, 2021, View Source [SID1234574560]). Anne White, senior vice president and president, Lilly Oncology, and Jacob Van Naarden, chief executive officer of Loxo Oncology at Lilly, will participate in a fireside chat at 11:00 a.m., Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On February 3, 2021 Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, reported that it will be presenting results from a recently completed Phase 2a clinical study of the company’s lead drug candidate, STP705, for treatment of squamous cell skin cancer, at the 19th Annual South Beach Symposium Medical Dermatology Summit (Press release, Sirnaomics, FEB 3, 2021, View Source [SID1234574559]). The virtual conference runs from Feb. 5-7, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Innovation in the Treatment of NMSC: siRNA STP705 for SCC in situ
Presented by: Mark Steven Nestor, M.D., Ph.D.; Director, Center for Cosmetic Enhancement, Center for Clinical and Cosmetic Research in Aventura, Florida
The presentation will be available for viewing for one year via the conference website, starting at 2:45PM ET on Saturday, February 6, 2021
About STP705
Sirnaomics’ leading product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expression. The product candidate has received IND approvals from both the US FDA and Chinese NMPA, including treatments for Liver cancer, non-melanoma skin cancer, and hypertrophic scar. STP705 has also received three Orphan Drug Designations from the US FDA for treatment of cholangiocarcinoma, primary sclerosing cholangitis and Hepatocellular Carcinoma. Preclinical animal models, as well as recent human tissue analysis from our isSCC study using STP705, have demonstrated statistically significant gene target knockdown as well as reduction in many tumor biomarkers that are common to multiple different tumor types. We have also witnessed in both our animal and human data improvement in T-cell penetration in multiple tumor types. These effects may lead to improved tumor response via oncogenic biomarker reduction and increase in T-cell penetration, which has the potential to enhance the activity of traditional chemotherapy and immune checkpoint inhibitor efficacies via T-cell enhancement. Based on the results of the STP705 Phase 2a trial, Sirnaomics intends to initiate a Phase 2b trial of STP705 in patients with isSCC, Bowen’s disease.

On February 3, 2021 Veracyte, Inc. (Nasdaq: VCYT) (the "Company") reported that it has commenced an underwritten public offering of $400.0 million in shares of its common stock (Press release, Veracyte, FEB 3, 2021, View Source [SID1234574558]). All of the shares are being offered by Veracyte. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million in shares of its common stock at the public offering price, less underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Veracyte intends to use the net proceeds from the offering, together with its existing cash, to finance its acquisition of Decipher Biosciences, Inc. Veracyte intends to use the remaining net proceeds from the offering for working capital and other general corporate purposes, which may include acquisitions or investments in complementary businesses, technologies or other assets, although it has no present commitments or agreements to do so (other than with respect to Decipher Biosciences, Inc.).

Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint lead book-running managers for the offering, William Blair & Company, L.L.C. is acting as a book-running manager and BTIG, LLC, Needham & Company, LLC, and Lake Street Capital Markets, LLC are acting as co-managers.

The shares will be issued pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on February 3, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by email at [email protected], or by telephone at (866) 471-2526; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 01220, by email at [email protected], or by telephone at (800) 808-7525, ext. 6105.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

On February 3, 2021 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that management will participate in the following investor conferences in February (Press release, ORIC Pharmaceuticals, FEB 3, 2021, View Source [SID1234574557]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks 2021 Oncology Day – Participating in a virtual fireside chat on February 11, 2021 at 1:00 p.m. ET/10:00 a.m. PT; and

LifeSci Partners Precision Oncology Day – Hosting virtual investor meetings on February 17, 2021.
A live webcast of the fireside chat will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.

On February 3, 2021 Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, reported that it intends to sell, subject to market and other conditions, $50 million of shares of its common stock in an underwritten public offering (Press release, Kaleido Biosciences, FEB 3, 2021, View Source [SID1234574556]). Kaleido also intends to grant the underwriters a 30-day option to purchase an additional $7.5 million of shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by Kaleido.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley and Piper Sandler are acting as joint book-running managers for the offering.

Kaleido intends to use the net proceeds from the offering, in addition to its existing cash resources, to fund its continued research and development activities, including the completion of the ongoing clinical studies of KB109 in patients with mild-to-moderate COVID-19 and the ongoing clinical study of KB295 in patients with mild-to-moderate ulcerative colitis; to conduct additional studies or initiate preparation for commercialization of KB109 if current studies in patients with mild-to-moderate COVID-19 are successful; to generate additional data and/or begin clinical studies in other areas such as immuno-oncology, cardiometabolic and liver diseases and diseases associated with pathogens; to fund any other research and development activities that relate to its current and future clinical and preclinical activities; and the remainder for planned general and administrative expenses, working capital and other general corporate purposes.

The securities described above are being offered by Kaleido pursuant to a shelf registration statement on Form S-3 (No. 333-240323), including a base prospectus. The securities will be offered only by means of a prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 and Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.